Prof. Dr. Neva Caliskan Lehrstuhl Biochemie III 93053 Regensburg Tel: +49 941 9432471 E-Mail: [email protected] ...

Many new names sounded as if they’d been cooked up by a medieval monk. HIV-1 would henceforth be known as Lentivirus ...

Dec. 10, 2024 — A newer vaccine against hepatitis B virus was clearly superior to an older vaccine type in inducing a protective antibody response among people living with HIV who didn't respond ...

The global rapid RNA testing kits market, valued at approximately USD 5,890.0 Million in 2021, is set to experience impressive growth, with projections indicating a robust 6.8% CAGR, pushing the ...

Thus, the initial hope that the identification of HIV-specific elements of the immune system in HIV-infected individuals would lead to better therapies and vaccines has been replaced by the ...

Needlestick injuries—as well as any percutaneous injury that can expose a person to tainted blood or body fluids—have long been a concern to both healthcare workers and the public at large. Many of ...

Highly active antiretroviral therapy (HAART) has led to a dramatic decline in human immunodeficiency virus (HIV ... it correlates well with the plasma HIV RNA, supporting its value in HIV ARV ...

Jan. 1, 2025 — Researchers have traced a cellular route Ebola virus (EBOV) uses to traverse the inner and outer layers of skin and emerge onto the skin's surface. The study identifies new cell ...

Eight in 10 infants received respiratory syncytial virus (RSV) protection during the 2023 to 2024 season, according to a research letter published online Jan. 8 in JAMA Network Open.

With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.

Overview: In Uganda alone, frequent FMD outbreaks have resulted in losses amounting to millions annually. Between 2015 and ...